Deodhar A, Blanco R, Dokoupilova E, et al. - This study was sought to present the primary (1‐year) outcomes from PREVENT, the first phase III study assessing secukinumab in individuals with active non-radiographic axial spondyloarthritis (SpA). Researchers randomized a total of 555 patients in a 1:1:1 ratio to receive subcutaneous secukinumab 150 mg with a loading dose (loading dose [LD] group), secukinumab 150 mg without a loading dose (non–loading dose [NL] group), or placebo weekly and then every 4 weeks starting at week 4. A total of 481 patients were included who completed 52 weeks of treatment, including 84.3% (156 of 185) in the LD group, 89.7% (165 of 184) in the NL group, and 86.0% (160 of 186) in the placebo group. The data revealed that secukinumab 150 mg gives a significant and sustained improvement in signs and symptoms of nonradiographic axial SpA through 52 weeks. Safety was consistent with previous reports.